



B cell events at a glance

21st–24th June 2006, Amsterdam RAI



Wednesday 21st June

Roche Targeting B cell stand – 09.30–17.15, Hall 8 – Stand 602



Thursday 22nd June

Oral presentations – 10.15–11.45, Hall 10

OP0016

Prevention of joint structural damage at 1 year with rituximab in RA patients with an inadequate response to one or more TNF inhibitors (REFLEX study)

Edward Keystone

OP0017

Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to one or more DMARDs

Paul Emery

Poster presentations – 11.45–13.30, Exhibition Area

THU0206

Safety of TNF inhibitors in RA patients previously treated with rituximab

Ferdinand Breedveld

THU0552

Economic consequences of providing rituximab as a new therapeutic option for RA in the UK

Gavin Lewis

THU0193

Efficacy of rituximab in patients with RA refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice

Noemie Assous

THU0207

Relationship between clinical response, rituximab pharmacokinetics and peripheral B cell levels in RA

Ferdinand Breedveld

THU0211

Oral glucocorticoids have no impact on the efficacy or safety profile of rituximab in RA patients with inadequate response to TNF inhibitors (REFLEX study)

Gerd Burmester

THU0220

Prolonged efficacy of rituximab in RA patients with inadequate response to one or more TNF inhibitors: 1-year follow-up of a subset of patients receiving a single course in a controlled trial (REFLEX) study

Stanley Cohen

THU0226

Specific peripheral blood B-lineage cells predict response to rituximab therapy in RA: a study with high sensitivity flow cytometry

Shouvik Dass

THU0227

Response to rituximab therapy in RA correlates with variable B cell expression in peripheral blood and synovium

Shouvik Dass

THU0228

Efficacy of rituximab treatment and further courses of treatment in patients with RA is not dependent on rheumatoid factor seroreversion

Salvatore de Vita

THU0235

Monitoring of gene expression in patients with RA treated with anti-CD20 (rituximab) applying DNA-chip technology

Susanne Drynda

THU0240

Prolonged efficacy of rituximab in RA patients with inadequate response to methotrexate: 1-year follow-up of a subset of patients receiving a single course in a controlled trial (DANCER trial)

Paul Emery

THU0521

Cost analysis of introducing rituximab as new treatment approach for RA: the Spanish perspective

Concha Alvarez

THU0533

Pharmacoeconomic model using microsimulation to assess impact of providing rituximab for treatment of RA: the Italian perspective

Ben Brown

Roche Targeting B cell stand – 09.30–17.15, Hall 8 – Stand 602



Friday 23rd June

Oral presentations – 15.30–17.00, Hall 9a

OP0179

Efficacy and safety of rituximab in active RA patients who experienced inadequate responses to one or more TNF inhibitors

Stanley Cohen

Poster presentations – 11.45–13.30, Exhibition Area

FRI0125

Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to one or more TNF inhibitors

Edward Keystone

FRI0126

Rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study

Adrian Kielhorn

FRI0127

The value of rituximab for patients - a different perspective on adverse events data

Adrian Kielhorn

FRI0128

Rituximab in RA: translating ACR responses into benefit for the patients

Adrian Kielhorn

FRI0133

Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors

Joel Kremer

FRI0149

Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in RA patients in the DANCER trial

Philip Mease

FRI0151

Safety of rituximab in RA: results of a pooled analysis

Ronald van Vollenhoven

Symposium – 17.30–19.00, Auditorium

Sponsored by Roche

Targeting B Cells. A new perspective in RA

Speakers: Tore K. Kvien, Ferdinand Breedveld, Paul Emery, Edward Keystone, Josef S. Smolen

Roche Targeting B cell stand – 09.30–17.15, Hall 8 – Stand 602



Saturday 24th June

Poster presentations – 09.00–11.45, Exhibition Area

SAT0175

Repeat treatment with rituximab improves physical function and quality of life in patients with RA and an inadequate response to TNF inhibitors

Paul-Peter Tak

SAT0197

Response to rituximab in patients with RA is maintained by repeat therapy: results of an open-label trial

Ronald van Vollenhoven

SAT0497

Cost implications of introducing rituximab as a new treatment modality for RA in Germany

Susanne Schach

Roche Targeting B cell stand – 09.30–17.15, Hall 8 – Stand 602